by EpicentRx | Apr 17, 2024 | Blog, General
From time to time in this space, we will apply the phrase “Hot or Not?” to tumors from cases that we know or read about. This is clinically relevant because tumors that are hot or immune-infiltrated tend to respond better to therapies. It is the goal of EpicentRx lead...
by EpicentRx | Apr 16, 2024 | Blog
Not too long ago, we met Steve Young. Not the Steve Young, mind you, the Hall of Famer who quarterbacked the legendary San Francisco 49ers to a Super Bowl in 1994, but another Steve Young. Steven Young, to be precise, who, from our perspective, quarterbacks a...
by EpicentRx | Apr 15, 2024 | Blog
Tax evasion is much in the news of late. Penalties for it are harsh and may include fines or, imprisonment, or both, as several celebrities can attest to. Safe to assume they share – or at least can relate to – the darkly satirical anti-tax sentiment from...
by EpicentRx | Apr 15, 2024 | Blog
“Don’t turn up your nose at Nosism.” Nosism noun NO-siz-em Definition: to refer to oneself as “we,” which royals are known to do. Example sentences: “Nosism is a rare word, but it’s use is not, as exemplified by the EpicentRx blog posts, which are written by one...
by EpicentRx | Apr 12, 2024 | Blog
At the AACR conference in San Diego, Drs. Tony Reid, CEO of EpicentRx, and Anthony P. Conley, a sarcoma specialist at MD Anderson Cancer Center (MDACC), spoke with Biotech TV about lead EpicentRx therapy, AdAPT-001, which is currently under investigation in a Dr....
